<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01706484</url>
  </required_header>
  <id_info>
    <org_study_id>CRS-02</org_study_id>
    <secondary_id>2011-003623-35</secondary_id>
    <nct_id>NCT01706484</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis</brief_title>
  <official_title>A Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Assess Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Chronic Rhinosinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionorica SE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bionorica SE</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine whether 2 different dosages of a herbal extract&#xD;
      (240 and 480 mg/day) are more effective than placebo in the treatment of patients with&#xD;
      chronic rhinosinusitis (average reduction of investigator's Major Symptom Score over Visit 5&#xD;
      and Visit 6.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical trial population consists of patients presenting with two or more typical&#xD;
      symptoms of CRS and duration of symptoms of at least ≥12 weeks. The diagnosis should have&#xD;
      been confirmed with the initial diagnosis of CRS by nasal endoscopy and/or computer&#xD;
      tomography (CT) and by obligatory nasal endoscopy including exclusion of nasal polyps during&#xD;
      screening phase.&#xD;
&#xD;
      A total of 885 patients will be included in this clinical trial, which will last for&#xD;
      approximately 12 months, including screening, treatment and medication-free follow-up period&#xD;
      as well as final reporting. The duration for the individual patient is approximately 22 weeks&#xD;
      (Visit 1 - Visit 7). After a 2-week screening phase, treatment will be started by application&#xD;
      of either 240 mg or 480 mg daily dose (t.i.d.) or placebo for 12 weeks followed by a&#xD;
      medication-free follow-up period.&#xD;
&#xD;
      Symptoms often do not correlate to the findings in nasal endoscopy or CT. Therefore, efficacy&#xD;
      in this clinical trial is defined as per clinical definition using five individual&#xD;
      rhinosinusitis symptoms (MSS)graded by the investigator using increasing severity grading(0 =&#xD;
      absent [none / not present], 1 = mild, 2 = moderate, 3 = severe).&#xD;
&#xD;
      Secondary outcome measures include&#xD;
&#xD;
        -  single rhinosinusitis symptoms of CRS (MSSINV and MSSPAT),&#xD;
&#xD;
        -  Work Productivity and Activity Impairment patient questionnaire related to General&#xD;
           Health [WPAI:GH],&#xD;
&#xD;
        -  total symptom severity by Visual Analogue Scale&#xD;
&#xD;
        -  response to treatment rated by investigator and patient&#xD;
&#xD;
        -  20-Question Sino-Nasal Outcome Test [SNOT-20, only Germany]&#xD;
&#xD;
        -  percentage of patients with permitted concomitant medication for the treatment of CRS&#xD;
&#xD;
        -  premature termination due to exacerbations of symptoms&#xD;
&#xD;
        -  post treatment course of CRS will&#xD;
&#xD;
        -  pharmacoeconomic assessments&#xD;
&#xD;
        -  safety and tolerability of trial treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average of investigator's Major Symptom Score ratings [score points] at V5 and V6</measure>
    <time_frame>4 weeks</time_frame>
    <description>The primary efficacy endpoint is defined as the average of investigator's Major Symptom Score ratings [score points] at V5 and V6 (arithmetic mean of 2 ratings).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient´s MSS ratings [score points] from V5 to V6</measure>
    <time_frame>4 weeks</time_frame>
    <description>Arithmetic mean of approximately 28 ratings, Diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigtor´s MSS ratings [score points] at V3</measure>
    <time_frame>Day 8</time_frame>
    <description>CRF data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator´s MSS ratings [score points] at V4</measure>
    <time_frame>Day 29</time_frame>
    <description>CRF data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigtor´s MSS ratings [score points] at V5</measure>
    <time_frame>Day 57</time_frame>
    <description>CRF data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigtor´s MSS ratings [score points] at V6</measure>
    <time_frame>Day 85</time_frame>
    <description>CRF data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigtor´s MSS ratings [score points] at V7</measure>
    <time_frame>Day 141</time_frame>
    <description>CRF data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responders based on investigators´ ratings at V2, V3, V4, V5, V6 and V7</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responders based on patients´ ratings at V2, V3, V4, V5, V6 and V7</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>CRS-related absenteeism from work</measure>
    <time_frame>20 weeks</time_frame>
    <description>CRF data</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">927</enrollment>
  <condition>Chronic Sinusitis</condition>
  <arm_group>
    <arm_group_label>80 mg BNO 1016 und placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 tablets (one containing 80 mg BNO 1016 and one placebo) by mouth 3 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>160 mg BNO 1016</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 tablets (each containing 80 mg BNO 1016) by mouth 3 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 tablets (each without BNO 1016) by mouth 3 times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BNO 1016</intervention_name>
    <description>comparison of different dosages of drug and placebo</description>
    <arm_group_label>160 mg BNO 1016</arm_group_label>
    <arm_group_label>80 mg BNO 1016 und placebo</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>herbal plant extract,</other_name>
    <other_name>sinupret extract mite</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent including data protection declaration&#xD;
&#xD;
          -  Male and female outpatients aged ≥18 and ≤75 years&#xD;
&#xD;
          -  Diagnosis of bilateral chronic rhinosinusitis without nasal polyps confirmed by:&#xD;
&#xD;
               -  nasal endoscopy during the screening period (nasal endoscopy results not older&#xD;
                  than 2 month will be accepted) to confirm inflammation, mucopurulent discharge&#xD;
                  and/or oedema/mucosal obstruction primarily in middle meatus without nasal polyps&#xD;
                  being present&#xD;
&#xD;
               -  at the discretion of the investigator a historic CT (before screening and not&#xD;
                  older than 24 months) will be considered additionally for confirmation of&#xD;
                  bilateral involvement of middle meatus and paranasal sinuses without resolution&#xD;
                  of symptoms (mucosal changes within the ostiomeatal complex and/or sinuses)&#xD;
&#xD;
          -  Bilateral chronic rhinosinusitis characterized by (V1 and V2):&#xD;
&#xD;
               -  presence of chronic rhinosinusitis symptoms for at least 12 weeks without&#xD;
                  complete resolution of symptoms prior to enrolment (V1)&#xD;
&#xD;
               -  a MSS ≥6 points and ≤12 points for each of the screening days observed by diary&#xD;
                  entries (MSSPAT)and on the days of Visit 1 and 2 (MSSINV)&#xD;
&#xD;
               -  on 5 random days of the screening period (or at least at days -5 to -1) assessed&#xD;
                  by MSSPAT and on the day of Visit 1 and 2 assessed by MSSINV: rhinorrhoea&#xD;
                  (anterior or posterior) and pain (facial pain or headache) of at least moderate&#xD;
                  intensity (score ≥2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sinus surgery within the last 2 years (solitary sinus puncture is allowed)&#xD;
&#xD;
          -  Nasal concha surgery within the last 3 months&#xD;
&#xD;
          -  Presence or history of uni- or bilateral nasal polyps&#xD;
&#xD;
          -  Presence of moderate to severe co-morbid asthma, including allergic asthma&#xD;
&#xD;
          -  Patients with mild asthma having exacerbations within 30 days prior to trial inclusion&#xD;
&#xD;
          -  Patients with cystic fibrosis&#xD;
&#xD;
          -  Patients with a positive skin prick test at V1 against allergens to which the patient&#xD;
             might be exposed to during the expected individual trial duration, if clinically&#xD;
             relevant (results not older than 12 months will be accepted)&#xD;
&#xD;
          -  Clinically relevant perennial (e.g. patients with actual clinical symptoms of allergic&#xD;
             rhinitis against house dust/-mite antigen) or actual seasonal allergic rhinitis&#xD;
&#xD;
          -  Rhinitis medicamentosa (drug induced rhinitis)&#xD;
&#xD;
          -  Aspirin-Exacerbated Respiratory Disease [AERD] (Aspirin sensitivity)&#xD;
&#xD;
          -  Dentogenic sinusitis or otherwise unilateral sinusitis&#xD;
&#xD;
          -  Presence of anatomical deviations of the nasal septum that significantly impair nasal&#xD;
             and paranasal ventilation / airflow&#xD;
&#xD;
          -  Known hypersensitivity to trial medication or excipients&#xD;
&#xD;
          -  Patients with rare hereditary problems of fructose intolerance, galactose intolerance,&#xD;
             lactase deficiency or glucose-galactose malabsorption or sucrase-isomaltase&#xD;
             insufficiency&#xD;
&#xD;
          -  Signs or symptoms of acute bacterial sinusitis (e.g. fever &gt; 38.5°C, orbital&#xD;
             complications,severe unilateral frontal headache or toothache)&#xD;
&#xD;
          -  Treatment with systemic or nasal antibiotics or corticosteroids within the last 4&#xD;
             weeks prior to V1&#xD;
&#xD;
          -  Treatment with decongestant preparations (α-sympathomimetics), analgesics (including&#xD;
             systemic Non-Steroidal Inflammatory Drugs [NSAIDs], except paracetamol), mucolytics /&#xD;
             secretolytics, antihistamines, or alternative medicine preparations for treatment of&#xD;
             common cold like symptoms or with immunomodulating properties within the last 7 days&#xD;
             prior to V1&#xD;
&#xD;
          -  Patients with gastric or duodenal ulcer&#xD;
&#xD;
          -  Other diseases within 5 years prior to V1, which in the opinion of the investigator&#xD;
             disqualifies the patient for trial enrolment (e.g. liver or kidney disease, severe&#xD;
             somatopathic, neurological and /or psychiatric diseases, history of malignancy or&#xD;
             alcohol or drug abuse or immunodeficiency).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Bachert, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghent University Hospital; Ear, Nose, Throat Medicine, Head &amp; Neck Surgery; Upper Airway Research Laboratory - UZ Gent; De Pintelaan 185 / 1P1; 9000 Gent; Belgium.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Claus Bachert, Prof. Dr.</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>September 4, 2012</study_first_submitted>
  <study_first_submitted_qc>October 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2012</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>randomized clinical trial</keyword>
  <keyword>chronic rhinosinusitis</keyword>
  <keyword>herbal extract BNO 1016</keyword>
  <keyword>exacerbation</keyword>
  <keyword>pharmacoeconomic</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

